Menu
Back to Journals » Drug Design, Development and Therapy » Volume 7
New treatments for myasthenia: a focus on antisense oligonucleotides
Authors Angelini C , Martignago S, Bisciglia M
Received 7 May 2012
Accepted for publication 31 July 2012
Published 10 January 2013 Volume 2013:7 Pages 13—17
DOI https://doi.org/10.2147/DDDT.S25716
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Corrado Angelini,1 Sara Martignago,2 Michela Bisciglia2
1IRCCS S Camillo, Via Alberoni, Venice, Italy; 2Department of Neurosciences, University of Padova, Via Giustiniani 5, 35128, Padova, Italy
Abstract: Autoimmune myasthenia gravis (MG) is a neuromuscular disorder caused by autoantibodies directed against the acetylcholine receptor (AChR). Current symptomatic therapy is based on acetylcholinesterase (AChE) drugs. The available long-term current therapy includes steroids and other immunomodulatory agents. MG is associated with the production of a soluble, rare isoform of AChE, also referred as the “read-through” transcript (AChE-R). Monarsen (EN101) is a synthetic antisense compound directed against the AChE gene. Monarsen was administered in 16 patients with MG and 14 patients achieved a clinically significant response. The drug is now in a Phase II study. Further investigations are required to confirm its long-term effects.
Keywords: myasthenia gravis, antisense oligonucleotides, acetyl cholinesterase, EN101
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.